Last €27.55 EUR
Change Today +0.183 / 0.67%
Volume 72.8K
CLS1 On Other Exchanges
Symbol
Exchange
Xetra
OTC US
OTC US
As of 3:35 PM 02/26/15 All times are local (Market data is delayed by at least 15 minutes).

celesio ag (CLS1) Snapshot

Open
€27.50
Previous Close
€27.37
Day High
€27.72
Day Low
€27.36
52 Week High
02/26/15 - €27.72
52 Week Low
04/14/14 - €24.55
Market Cap
5.6B
Average Volume 10 Days
103.1K
EPS TTM
€0.46
Shares Outstanding
203.2M
EX-Date
07/16/14
P/E TM
59.9x
Dividend
€0.30
Dividend Yield
1.09%
Current Stock Chart for CELESIO AG (CLS1)

Related News

No related news articles were found.

celesio ag (CLS1) Related Businessweek News

No Related Businessweek News Found

celesio ag (CLS1) Details

Celesio AG, a trading company, provides logistics and services to the pharmaceutical and healthcare sector in 14 countries worldwide. The company operates through two divisions, Consumer Solutions and Pharmacy Solutions. The Consumer Solutions division offers prescription and non-prescription pharmaceuticals; various medical services at its pharmacies; and pharmaceutical care and advice on medicines. This division serves through approximately 2,200 owned pharmacies and 4,300 participants in its brand partnership schemes. The Pharmacy Solutions division is engaged in the wholesale of pharmaceuticals; and property development for pharmacies. It provides oncological products and other medicines for the treatment of complex diseases; and offers supplementary services for pharmacists, such as the organization and management of pharmacy cooperation programs. This division operates approximately 130 wholesale branches that supply to approximately 65,000 pharmacies and hospitals. The company was founded in 1835 and is headquartered in Stuttgart, Germany. As of Febriary 6, 2014, Celesio AG operates as a subsidiary of Dragonfly GmbH & Co. KGaA.

28,651 Employees
Last Reported Date: 10/28/14
Founded in 1835

celesio ag (CLS1) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

celesio ag (CLS1) Key Developments

Celesio AG Announces Revenue Results for the Year 2014

Celesio AG announced revenue results for the year 2014. For the period, the company generated group revenue of EUR 22,325.9 million, up 4.3% year-on-year. When adjusted for currency effects, revenue increased by 4.2%.

Celesio AG to Report Fiscal Year 2014 Results on Feb 05, 2015

Celesio AG announced that they will report fiscal year 2014 results on Feb 05, 2015

Celesio AG Reports Earnings Results for the First Nine Months of 2014; Provides Earnings Guidance for 2014

Celesio AG reported earnings results for the first nine months of 2014. For the period, on continuing operations basis, the company reported revenue of EUR 16,460.0 million against EUR 15,991.1 million a year ago. Market growth in Germany and Brazil and the good revenue performance in the United Kingdom and Norway outweighed the decline in France and Belgium. EBITDA was EUR 369.5 million against EUR 399.3 million a year ago. Adjusted EBITDA was EUR 410.2 million against EUR 406.9 million a year ago. EBIT was EUR 173.7 million against EUR 303.3 million a year ago. Adjusted EBIT was EUR 318.7 million against EUR 312.0 million a year ago. This is mainly due to the very good performance in the United Kingdom and Norway which more than compensated for the challenging circumstances caused by the discount competition in Germany, the weak market in France and an unfavourable trend in Brazil. Net profit was EUR 37.6 million against EUR 126.2 million a year ago. Adjusted net profit was EUR 174.0 million against EUR 132.1 million a year ago. Free cash outflow was EUR 271.5 million against free cash flow of EUR 33.3 million a year ago. Net financial debt was EUR 1,082.1 million against EUR 1,363.4 million a year ago. Net profit from continuing and discontinued operations was EUR 36.7 million or EUR 0.18 per basic share against net profit of EUR 120.8 million or EUR 0.68 per basic share a year ago. The company provided earnings guidance for 2014. Optimising the company's cost structures and level of efficiency is fundamental. The expansion of the European Pharmacy Network will also have a positive impact, enabling even stronger growth from 2015 onwards. However, these revenues will still be reduced in part by IT project costs in 2014. The unfavourable situation in Germany, France and Brazil is affecting earnings more than previously expected. The group has also faced higher allowances for debts in Portugal. Overall, adjusted EBIT in the 2014 fiscal year is expected to be slightly lower than in the prior year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLS1:GR €27.55 EUR +0.183

CLS1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cardinal Health Inc $88.17 USD -0.13
McKesson Corp $229.46 USD -0.14
UDG Healthcare PLC 467.40 GBp -7.70
Walgreens Boots Alliance Inc $81.65 USD +1.64
View Industry Companies
 

Industry Analysis

CLS1

Industry Average

Valuation CLS1 Industry Range
Price/Earnings 62.2x
Price/Sales 0.2x
Price/Book 1.8x
Price/Cash Flow 25.1x
TEV/Sales 0.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELESIO AG, please visit www.celesio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.